Table 1.
Demographic, clinical and pathological information of the GSE31684 and TCGA cohorts.
| GSE31684 | TCGA | |||
|---|---|---|---|---|
| Total | Training cohort | Validation cohort | Validation cohort | |
| No. of patients | 93 | 46 | 47 | 408 |
| Age (year) | ||||
| Mean | 69.1 | 68.6 | 69.7 | 68.1 |
| Range | 41.7~91.1 | 47.5~85.1 | 41.7~91.1 | 34.0~90.0 |
| Gender | ||||
| Male | 68(73.1%) | 33(71.7%) | 35(74.5%) | 301(73.8%) |
| Female | 25(26.9%) | 13(28.3%) | 12(25.5%) | 107(26.2%) |
| Tumor stage | ||||
| Ta/T1 | 15(16.1%) | 9(19.6%) | 6(12.8%) | 4(1.0%) |
| T2 | 17(18.3%) | 7(15.2%) | 10(21.3%) | 119(29.2%) |
| T3 | 42(45.2%) | 20(43.5%) | 22(46.8%) | 194(47.5%) |
| T4 | 19(20.4%) | 10(21.7%) | 9(19.1%) | 58(14.2%) |
| Unknown | 0 | 0 | 0 | 33(8.1%) |
| Tumor grade | ||||
| High | 6(6.5%) | 42(91.3%) | 45(95.7%) | 384(94.1%) |
| Low | 87(93.5%) | 4(8.7%) | 2(4.3%) | 21(5.1%) |
| Unknown | 0 | 0 | 0 | 3(0.8%) |
| Lymph node status | ||||
| Positive | 28(30.1%) | 13(28.3%) | 15(31.9%) | 129(31.6%) |
| Negative | 49(52.7%) | 25(54.3%) | 24(51.1%) | 237(58.1%) |
| Unknown | 16(17.2%) | 8(17.4%) | 8(17.0%) | 42(10.3%) |
| Adjuvant therapy | 35(37.6%) | 18(39.1%) | 17(36.2%) | 10(2.5%) |
| Smoking packs/year | ||||
| Mean | 35.2 | 35 | 35.4 | 39 |
| Range | 0~120 | 0~120 | 0~120 | 0~730 |
| Informed consent (yes) | 93(100%) | 46(100%) | 47(100%) | 408(100%) |
| OS (month) | ||||
| Mean | 47.5 | 51.6 | 43.4 | 27 |
| Range | 0.39~175.5 | 0.39~175.5 | 0.66~173.4 | 0.43~168.3 |
| Vital status | ||||
| Living | 28(30.1%) | 13(28.3%) | 15(31.9%) | 228(55.9%) |
| Dead | 65(69.9%) | 33(71.7%) | 32(68.1%) | 180(44.1%) |
| Recurrence/progression | 39(41.9%) | 20(43.5%) | 19(40.4%) | 141(34.6%) |
Informed consent were accomplished by researchers of the GSE31684 and TCGA cohorts; TCGA, The Cancer Genome Atlas; OS, overall survival.